Use of granulocyte type myeloid derived suppressor cell as diagnostic biomarker

A biomarker and cell-inhibiting technology, which is applied in the field of medical testing, can solve problems such as the absence of molecular biological indicators, achieve significant technological progress, avoid over-treatment, and improve survival rates

Inactive Publication Date: 2018-07-06
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no reliable molecular biological index that can predict which type of patients can benefit from NAC

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of granulocyte type myeloid derived suppressor cell as diagnostic biomarker
  • Use of granulocyte type myeloid derived suppressor cell as diagnostic biomarker
  • Use of granulocyte type myeloid derived suppressor cell as diagnostic biomarker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] 1.1 Preparation of peripheral mononuclear cell suspension (Periphera lblood mononuclear cell, PBMC)

[0015] Isolation of human peripheral mononuclear cells (PMBCs) is a fundamental procedure in immunology research. Currently, the commonly used methods for separating PBMCs are Ficoll density gradient centrifugation and Percoll density gradient centrifugation. In this experiment, we used Ficoll density gradient centrifugation, which can separate PBMCs simply, quickly and efficiently. The principle of separation is that there is a density difference between PBMC and other components such as red blood cells, platelets, and plasma in the blood. When an isotonic mixed solution is used for density gradient centrifugation, it will re-aggregate and stratify into four layers. The uppermost layer is plasma and platelets, the middle layer is lymphocyte separation fluid, the lowermost layer is red blood cells and granulocytes, and there is a white, opaque cloudy layer on the middl...

Embodiment 2

[0038] Example 2 A high proportion of G-MDSC is associated with NAC drug resistance and affects postoperative survival

[0039] Using SPSS, the effect of G-MDSCs on progression-free survival after neoadjuvant chemotherapy for bladder cancer was analyzed by Kaplan Meier univariate analysis. A high proportion of granulocytic myeloid-derived suppressor cells is associated with chemotherapy resistance, and a high proportion of patients has a progression-free survival time after surgery obviously decased( figure 2 A).

[0040] Using SPSS, the effect of G-MDSCs on tumor-specific survival after neoadjuvant chemotherapy for bladder cancer was analyzed by Kaplan Meier univariate analysis. A high proportion of granulocytic myeloid-derived suppressor cells is associated with chemotherapy resistance, and a high proportion of patients is tumor-specific after surgery. Significantly reduced survival time ( figure 2 B).

Embodiment 3

[0042] G-MDSC in the tumor microenvironment has a considerable relationship with neoadjuvant chemotherapy resistance. During the treatment of muscle-invasive bladder cancer, the median value of the above G-MDSC ratio is used as the cutoff point (cutoff value). Values ​​greater than the median were defined as high expression, and values ​​below the median were defined as low expression. For the median value of G-MDSCs ratio of 20.2% (2.1–45.6%), 6 patients in the high G-MDSCs group had pathological remission after chemotherapy, while 26 patients in the low G-MDSCs group had pathological remission, and there was a significant difference between the two ( P<0.001). There were 12 cases of pathological remission in patients with high M-MDSCs and 20 cases in patients with low M-MDSCs. There was no significant difference between them (P=0.078). If the patient's G-MDSC ratio is less than 20%, neoadjuvant chemotherapy can be performed first, and then radical cystectomy, which will hel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides use of a granulocyte type myeloid derived suppressor cell in the preparation of a diagnostic biomarker for diagnosing and predicting a neoadjuvant chemosensitivity effect of muscle-invasive bladder cancer. The invention further provides use of the granulocyte type myeloid derived suppressor cell in the preparation of a kit for diagnosing and predicting the neoadjuvant chemosensitivity effect of the muscle-invasive bladder cancer. The invention further provides a kit for diagnosing and predicting the neoadjuvant chemosensitivity effect of the muscle-invasive bladder cancer. The kit contains a reagent for detecting the granulocyte type myeloid derived suppressor cell. The invention discovers the granulocyte type myeloid derived suppressor cell as a novel biomarker fordiagnosing and predicting the neoadjuvant chemosensitivity effect of the muscle-invasive bladder cancer. A muscle-invasive bladder cancer patient with low-content granulocyte type myeloid derived suppressor cells can be sequentially subjected to neoadjuvant chemosensitivity and total cystectomy operation, so that the survival rate is increased, the excessive treatment is avoided, and the operationopportunity is not delayed.

Description

technical field [0001] The invention belongs to the field of medical detection, and relates to a granulocytic myeloid-derived suppressor cell, specifically, the use of the granulocyte-type myeloid-derived suppressor cell as a diagnostic biomarker. Background technique [0002] Bladder urothelial carcinoma (abbreviated as bladder cancer) is one of the most common malignant tumors. There are about 429,800 new cases of bladder cancer in the world every year, and 165,100 of them die from bladder cancer. Bladder cancer is the fourth most common malignant tumor in men in the United States, accounting for 7% of all malignant tumors, and the number of deaths ranks eighth. In my country, bladder cancer is the tumor with the highest incidence rate in the urinary system. The latest statistical data (2015) shows that the incidence rate is 80.5 / 100,000 and the mortality rate is 32.9 / 100,000. According to the degree of tumor invasion, primary bladder cancer can be divided into non-muscl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N15/10G01N15/14
CPCG01N15/10G01N15/14G01N2015/1006
Inventor 杨国良薄隽杰刘梦瑶张连华张岩
Owner RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap